Rewriting treatment for people with cancer and other serious diseases through epigenetic medicines

The company was founded on November 1, 2007 and is headquartered in Cambridge, Massachusetts.




190+ employees fully committed to helping patients with cancer and other serious diseases









Investigational agents lack regulatory approval required for commercialization and patient use.

*RNA and DNA helicase.

CRISPR, clustered regularly interspaced short palindromic repeats; HAT, histone acetyltransferase; HMT, histone methyltransferase; HMTi, histone methyltransferase inhibitor; NDA, New Drug Application; RMTi, arginine methyltransferase inhibitor.

Epizyme has a rich history of epigenetic innovation and research partnerships

>10 candidate-quality compounds identified

4 new chemical entities in clinical development

Discovered multiple first-in-class molecules



www.epizyme.com
400 Technology Square, Cambridge, MA 02139
(617) 229-5872
© 2020 Epizyme, Inc. All Rights Reserved
CO-ES-CP-20-0001